GLP-1 Medications and Mood: What Psychiatrists Are Watching

Written by the Prescribed Wellness Psychiatry team · Medically reviewed by Veronica Sanchez, MD · Updated October 2026

GLP-1 medications such as Wegovy, Ozempic and Zepbound do not appear to raise the risk of depression or suicidal thoughts. In January 2026 the FDA reviewed 91 clinical trials and a study of more than 2 million people, found no increased risk, and asked drugmakers to remove the suicide warning from the weight-loss labels. Mood changes are still worth telling your doctor about.
That is reassuring news, and it is not the whole story. Psychiatrists are watching these medications for other reasons too: how they interact with psychiatric medications, whether they can help with weight gain from those medications, and early research on cravings and alcohol. Here is what we know, and what we do not know yet.
Key takeaways✓ The FDA found no increased risk of suicidal thoughts or behavior with GLP-1 medications after a large review in January 2026. ✓ The FDA still asks people taking these medications to report new or worsening depression or unusual mood changes to their doctor. ✓ GLP-1 medications slow down the stomach, which can change how other pills you swallow are absorbed, including psychiatric medications. ✓ One clinical trial found that liraglutide helped people taking clozapine or olanzapine lose weight and improve blood sugar, but this is an off-label use. ✓ Early research on alcohol cravings is promising but small, and no GLP-1 medication is approved to treat alcohol use disorder. |
What are GLP-1 medications?
GLP-1 medications are drugs that copy a hormone your gut makes after you eat. GLP-1 stands for glucagon-like peptide-1. These medications lower blood sugar, make you feel full sooner, and slow down how fast food leaves your stomach.
The best-known names are semaglutide (sold as Ozempic for diabetes and Wegovy for weight), tirzepatide (Mounjaro and Zepbound), and liraglutide (Victoza and Saxenda). Tirzepatide also acts on a second gut hormone, called GIP, but it is usually grouped with the others. The FDA's January 2026 safety communication covers this whole family.
Do GLP-1 medications cause depression or suicidal thoughts?
The best evidence we have says no. In its January 13, 2026 Drug Safety Communication, the FDA reported on 91 placebo-controlled trials with 107,910 people. It found no increased risk of suicidal thoughts or behavior, or of other related psychiatric side effects. The FDA also ran its own Sentinel study of insurance claims from more than 2.2 million new users, comparing GLP-1 medications with another class of diabetes drugs. That study found no increased risk of intentional self-harm.
Based on that review, the FDA asked the makers of Saxenda, Wegovy and Zepbound to remove the suicidal behavior and ideation warning from their labels. The current Wegovy prescribing information lists that warning as removed in January 2026. GLP-1 medications approved only for diabetes never carried the warning.
Some research points the other way, toward lower risk. A 2024 study in Nature Medicine by Wang and colleagues looked at health records from more than 1.5 million people with type 2 diabetes and more than 230,000 people with obesity or overweight. People taking semaglutide had fewer new or repeat diagnoses of suicidal thoughts over six months than people on other weight or diabetes medications. The authors are clear that this kind of study cannot prove cause, so we read it as "no sign of harm," not as proof that the drug protects mood.
If you are having thoughts of harming yourself right now, call or text 988 to reach the Suicide & Crisis Lifeline, or call 911. You do not need to wait for an appointment.
If the risk is not higher, why are psychiatrists still paying attention?
Because a population-level finding does not tell you how one person will feel. The FDA itself still tells patients to let their health care professional know about new or worsening depression, suicidal thoughts, or any unusual changes in mood or behavior. That advice is in the same communication that removed the warning.
There are also ordinary reasons mood can shift during a big change in eating and weight. Appetite changes, nausea, tiredness, changes in sleep and the stress of a new routine can all affect how you feel day to day. None of that means the medication is wrong for you. It means mood is worth tracking, the same way blood sugar is.
If you have a history of an eating disorder, tell both your prescriber and your psychiatrist before starting a medication that changes appetite. That conversation belongs at the start, not after something goes wrong.
Can GLP-1 medications help with weight gain from psychiatric medication?
There is real evidence for this, though it is still limited. Some antipsychotic medications, especially clozapine and olanzapine, often cause weight gain and higher blood sugar. We cover that in more detail in our post on weight changes on psychiatric medication.
A 2017 randomized trial in JAMA Psychiatry by Larsen and colleagues enrolled 103 adults with schizophrenia-spectrum disorders who were stable on clozapine or olanzapine and had prediabetes. After 16 weeks, the group taking liraglutide lost about 5.3 kilograms (around 12 pounds) more than the placebo group. Blood sugar returned to normal in 63.8% of the liraglutide group compared with 16.0% on placebo. Nausea was more common with liraglutide.
This is one trial, and using a GLP-1 medication for antipsychotic weight gain is off-label, meaning the FDA has not approved it for that purpose. Coverage for these medications also varies widely by plan. Still, for someone who needs an antipsychotic and is struggling with its effects on weight, it is a fair question to raise with your psychiatrist and your primary care doctor together.
Can GLP-1 medications change how my other medications work?
They can. GLP-1 medications slow down how fast your stomach empties. The Wegovy prescribing information says this delay has the potential to affect how other medications you take by mouth are absorbed, and advises monitoring their effects.
For psychiatric medications, that matters most when small changes in blood level make a big difference. If you take a mood stabilizer, an antipsychotic, or any medication where your prescriber checks levels or watches closely, make sure every prescriber knows about the GLP-1. Please do not stop or change a psychiatric medication on your own because of this. The National Institute of Mental Health notes that stopping a medication too soon or too suddenly can cause unpleasant or harmful effects. Changes should be planned with your prescriber.
Do GLP-1 medications reduce alcohol cravings?
Early research says they might, but it is too soon to call it a treatment. A 2025 randomized trial in JAMA Psychiatry by Hendershot and colleagues gave 48 adults with alcohol use disorder either low-dose semaglutide or placebo for nine weeks. The semaglutide group drank less in a lab drinking session, had fewer drinks on the days they drank, and reported less craving. It did not reduce the number of days they drank.
The same team later tested semaglutide in 24 adults who smoked daily. In that 2026 trial in JAMA Network Open, it reduced craving and body weight but did not significantly reduce cigarettes per day. Both studies were small and short. No GLP-1 medication is FDA-approved for alcohol use disorder or smoking. If you are worried about your drinking, there are proven treatments available now, and that is a good conversation to have with a psychiatrist.
What should I tell my psychiatrist if I start a GLP-1 medication?
The name of the medication, the date you started, and who prescribes it.
Every other medication and supplement you take, including anything for mood, sleep, focus or anxiety.
Any change in mood, sleep, energy, motivation or anxiety since you started, even if it seems small.
Side effects like nausea or vomiting, which can make it harder to keep other pills down.
Any history of an eating disorder, or any worry about how you are eating now.
Whether you are thinking about stopping the GLP-1, so a plan can be made with both prescribers.
What does this look like at Prescribed Wellness Psychiatry?
A good psychiatric evaluation covers every medication you take, not just the psychiatric ones. The American Psychiatric Association's practice guideline for evaluating adults calls for a review of all medications and supplements as part of a full evaluation. A GLP-1 medication belongs on that list.
At Prescribed Wellness Psychiatry, a first evaluation with Dr. Sanchez is 50 minutes and follow-up visits are 25 minutes. Visits are in English or Spanish. You can come in person to our office at 3800 Barham Blvd, Suite 416, in the Cahuenga Pass, with parking in the building. We are next door to the Warner Bros. lot and about a minute from Burbank, which makes us easy to reach from Toluca Lake and Studio City. You can also meet by secure video from anywhere in California.
We are enrolled with Medicare in California. That means Medicare patients can see us in person in Los Angeles or by video from home elsewhere in the state, including Bakersfield and San Diego. Learn more on our Medicare psychiatry page.
How do I get started?
If you are starting a GLP-1 medication and already take psychiatric medication, or you have noticed changes in your mood since starting one, a visit is a reasonable next step. You can call or text (626) 681-3729, or request an appointment online. If this is your first visit, our guide to what to expect at your first psychiatric evaluation walks through it step by step.
Frequently asked questions
Does Ozempic or Wegovy cause depression?
Current evidence says no. In January 2026 the FDA reviewed 91 clinical trials and a study of more than 2 million people and found no increased risk of suicidal thoughts or related psychiatric side effects with GLP-1 medications. The FDA still asks patients to report new or worsening depression or unusual mood changes to their doctor.
Why was the suicide warning removed from GLP-1 weight-loss labels?
The FDA asked drugmakers to remove it after a large review found no increased risk. That review covered 91 placebo-controlled trials with 107,910 people and an FDA Sentinel study of more than 2.2 million new users. The FDA said the evidence does not support a causal link between GLP-1 medications and suicidal thoughts or behavior.
Can I take a GLP-1 medication with my antidepressant?
Many people take both, but that decision belongs to you and your prescribers. GLP-1 medications slow stomach emptying, which can change how other pills are absorbed, so every prescriber should know about every medication you take. Do not stop or change a psychiatric medication on your own; plan any change with your prescriber.
Do GLP-1 medications help with weight gain from antipsychotics?
They may. A 2017 randomized trial found that liraglutide helped adults taking clozapine or olanzapine lose about 5.3 kilograms more than placebo over 16 weeks and improved blood sugar. This is one trial, and the use is off-label, so it is worth discussing with your psychiatrist and primary care doctor together.
Can semaglutide treat alcohol use disorder?
Not yet. A small 2025 trial of 48 adults found semaglutide reduced drinks per drinking day and alcohol craving over nine weeks, but it did not reduce the number of drinking days. No GLP-1 medication is FDA-approved for alcohol use disorder, and proven treatments are available now.
Sources
U.S. Food and Drug Administration. FDA requests removal of suicidal behavior and ideation warning from glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. Drug Safety Communication, January 13, 2026.
Novo Nordisk. WEGOVY (semaglutide) injection prescribing information, revised March 2026. FDA Drugs@FDA.
Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nature Medicine. 2024;30(1):168-176.
Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry. 2017;74(7):719-728.
Hendershot CS, Bremmer MP, Paladino MB, et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2025;82(4):395-405.
Hendershot CS, Bremmer MP, Paladino MB, et al. Once-weekly semaglutide in adults with daily cigarette use: a randomized clinical trial. JAMA Network Open. 2026;9(5):e2614898.
National Institute of Mental Health. Mental Health Medications.
American Psychiatric Association. Practice Guidelines for the Psychiatric Evaluation of Adults, Third Edition. 2015.
Medical disclaimer: This article is for general educational purposes and does not constitute medical advice, diagnosis, or treatment, nor a guarantee of insurance coverage. Coverage rules and costs change and vary by plan; always verify your benefits. If you are in crisis or thinking about harming yourself, call or text 988 (Suicide & Crisis Lifeline) or call 911.

